Everolimus and Early Calcineurin Inhibitor Withdrawal: 3-Year Results From a Randomized Trial in Liver Transplantation

The feasibility of de novo everolimus without calcineurin inhibitor (CNI) therapy following liver transplantation was assessed in a multicenter, prospective, open-label trial. Liver transplant patients were randomized at 4 weeks to start everolimus and discontinue CNI, or continue their current CNI-...

Descripción completa

Detalles Bibliográficos
Autores principales: Sterneck, M, Kaiser, G M, Heyne, N, Richter, N, Rauchfuss, F, Pascher, A, Schemmer, P, Fischer, L, Klein, C G, Nadalin, S, Lehner, F, Settmacher, U, Neuhaus, P, Gotthardt, D, Loss, M, Ladenburger, S, Paulus, E M, Mertens, M, Schlitt, H J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285226/
https://www.ncbi.nlm.nih.gov/pubmed/24502384
http://dx.doi.org/10.1111/ajt.12615

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285226/
https://www.ncbi.nlm.nih.gov/pubmed/24502384
http://dx.doi.org/10.1111/ajt.12615

Ejemplares similares